Vaxil BioVXLLF -85.27%38 Quick Ratio is 17.08 as of Mar. 2026, which is 326% above its 10-year median of 4.01. GuruFocus rates VXLLF with a GF Score™ of 38/100. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Vaxil Bio ranks better than 89.12% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Vaxil Bio's quick ratio for the quarter that ended in Mar. 2026 was 17.08.
Vaxil Bio has a quick ratio of 17.08. It generally indicates good short-term financial strength.
The historical rank and industry rank for Vaxil Bio's Quick Ratio or its related term are showing as below:
VXLLF'
s Quick Ratio Range Over the Past 10 Years
Min: 0.14 Med: 4.01 Max: 137
Current: 16.92
During the past 13 years, Vaxil Bio's highest Quick Ratio was 137.00. The lowest was 0.14. And the median was 4.01.
VXLLF's Quick Ratio is ranked better than 89.12% of 1416
companies
in the Biotechnology industry
Industry Median: 3.6
vs VXLLF: 16.92
Vaxil Bio (OTCPK:VXLLF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Vaxil Bio Quick Ratio Related Terms
Vaxil Bio Quick Ratio Historical Data
* Premium members only.
The historical data trend for Vaxil Bio's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vaxil Bio's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaxil Bio Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaxil Bio's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Vaxil Bio's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Vaxil Bio's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaxil Bio (VXLLF) has a Quick Ratio of 17.08 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vaxil Bio and its competitors. This is 326% above median its historical median of 4.01. Over the past decade, Vaxil Bio's Quick Ratio has ranged from 0.14 to 137.00. According to the industry distribution chart, Vaxil Bio ranks #154 out of 1416 companies in the Biotechnology industry, placing it in the top 10.9%.
Is Vaxil Bio's Quick Ratio too high?
Vaxil Bio's current Quick Ratio of 17.08 is 326% above median its 10-year median of 4.01. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 137.00. The Biotechnology industry median Quick Ratio is 3.60. Vaxil Bio's value of 17.08 is 374.4% above this industry median. Based on the distribution chart, Vaxil Bio ranks #154 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vaxil Bio has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Vaxil Bio's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vaxil Bio ranks #154 out of 1416 companies for Quick Ratio. This places Vaxil Bio in the top 11% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Vaxil Bio's value of 17.08 is 374.4% above this benchmark. Historically, Vaxil Bio's own Quick Ratio has ranged from 0.14 to 137.00 over the past decade. While the company's 10-year median is 4.01 vs. the industry median of 3.60, Vaxil Bio has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaxil Bio's current Quick Ratio of 17.08 is 374.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vaxil Bio and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaxil Bio's current Quick Ratio is 17.08, which is 326% above median its own 10-year median of 4.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaxil Bio stock overvalued right now?
Vaxil Bio (VXLLF) has a current Quick Ratio of 17.08. The current Quick Ratio is 17.08, which is 326% above median its 10-year median of 4.01 and 374.4% above the Biotechnology industry median of 3.60. Vaxil Bio's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Vaxil Bio (VXLLF), the current Quick Ratio is 17.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vaxil Bio Ltd is a biotechnology company focused on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. In recent years, the Company has been more focused on P-EsbpDOX. The Company develops ImMucin, a MUC1 SP-derived vaccine that has completed a Phase 1/2 clinical trial for the treatment of multiple myeloma. It is also developing SP-based COVID-19 and tuberculosis vaccine/treatment candidates.
38GF Score
Get the complete analysis for VXLLF
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VXLLF has been successfully added to your 
